Clinical Trial Update: Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder [Phase 3]

View source ↗

Summary

Phase 3 open-label study evaluating intramuscular aripiprazole (OPC-14597) for maintenance treatment in Bipolar I disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• aripiprazole (OPC-14597) (aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Bipolar I | Phase 3 | Status: COMPLETED | Results posted: 2018-08-08